Milestone Pharmaceuticals (MIST) Enterprise Value (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Enterprise Value came in at -$184.2 million in Q1 2026, down 1594.26% YoY from $12.3 million in Q1 2025, and down 73.86% on a QoQ basis from -$106.0 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Enterprise Value (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Enterprise Value data on file, last reported at -$184.2 million in Q1 2026.
- Quarterly Enterprise Value fell 1594.26% year-over-year to -$184.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$184.2 million (down 1594.26% YoY) and the FY2025 annual result came in at -$106.0 million, down 51.99% from the prior year.
- Enterprise Value fell to -$184.2 million in Q1 2026, from -$106.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$10.9 million in Q1 2025 to a low of -$184.2 million in Q1 2026.
- A 5-year average of -$88.5 million and a median of -$79.4 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value soared 86.3% — and 2026, when it plunged 1594.26%.
- Tracing MIST's Enterprise Value over 5 years: stood at -$64.5 million in 2022, then declined by 2.21% to -$66.0 million in 2023, then slipped by 5.69% to -$69.7 million in 2024, then tumbled by 51.99% to -$106.0 million in 2025, then sank by 73.86% to -$184.2 million in 2026.
- The last three Enterprise Value figures came in at -$184.2 million (Q1 2026), -$106.0 million (Q4 2025), and -$118.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | -171.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -171.50 Mn |
| Mar 31, 2026 | -184.22 Mn |
| Dec 31, 2025 | -105.96 Mn |
| Sep 30, 2025 | -118.50 Mn |
| Jun 30, 2025 | -43.42 Mn |
| Mar 31, 2025 | -10.87 Mn |
| Dec 31, 2024 | -69.71 Mn |
| Sep 30, 2024 | -63.62 Mn |
| Jun 30, 2024 | -69.99 Mn |
| Mar 31, 2024 | -79.35 Mn |
| Dec 31, 2023 | -65.96 Mn |
| Sep 30, 2023 | -141.57 Mn |
| Jun 30, 2023 | -87.59 Mn |
| Mar 31, 2023 | -128.00 Mn |
| Dec 31, 2022 | -64.54 Mn |
| Sep 30, 2022 | -77.23 Mn |
| Jun 30, 2022 | -86.24 Mn |
| Mar 31, 2022 | -108.20 Mn |
| Dec 31, 2021 | -114.14 Mn |
| Sep 30, 2021 | -141.40 Mn |